BNP in SOB

The impact of measuring brain type natriuretic peptide in patients with shortness of breath in the emergency department on management and subsequent patient mortality and morbidity.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000350628

Acronym

BNPSOB

Enrollment

600

Registered

2005-09-09

Start date

2005-08-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To evaluate whether testing levels of BNP in patients presenting with shortness of breath has an impact on the management of these patients in the emergency department

Interventions

To evaluate the role of B-type natriuretic peptide (BNP) in the management of patients presenting to the emergency department with the presenting symptom of shortness of breath (SOB). Patients randomised to the study group will have BNP levels tested. In the test group with a positive BNP result doctors will be encouraged to use a standardised approach to the optimum treatment of CCF. Blood is taken for BNP levels upon patient arrival and results will be available within one hour. The study du

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Presenting complaint of SOB, of triage categories 1-3.

Exclusion criteria

Trauma patients, patients with renal failure or patients in cardiogenic shock.

Outcome results